Senate mandates antidote stocking after preventable snakebite death

Ifunanya Nwangene died Saturday doing what thousands of Nigerians do when facing medical emergencies: rushing between hospitals searching for treatment that should be standard but isn't.

The 26-year-old Abuja-based singer, known professionally as Nanyah, suffered a snakebite at her residence. She visited two hospitals seeking anti-venom. Neither had it. By the time she reached Federal Medical Centre Abuja—which claims it had anti-venom and administered it—the delay proved fatal.

Tuesday, the Senate responded. Senator Idiat Adebule sponsored a motion calling for mandatory stocking of essential antidotes in all hospitals. Lawmakers described Nwangene's death as "tragic and avoidable," exposing "serious gaps in emergency preparedness."

The Senate directed the Ministry of Health to develop national guidelines mandating minimum stock levels of antivenoms, anti-toxins, and emergency medicines. They told health regulators to make antidote stocking a licensing requirement for private hospitals. They asked the Ministry of Information to run public sensitisation campaigns about the "golden hour" for treatment.

It's a pattern: tragedy first, regulation second. The World Health Organisation classifies snakebite as a neglected tropical disease requiring urgent attention in countries like Nigeria where an estimated 2,000 people die annually from snakebites. Yet it took a musician's viral death to trigger Senate action.

Here's what the resolution reveals: Nigerian hospitals—public and private—operate without mandatory emergency preparedness standards. Licensing and accreditation don't require stocking life-saving drugs. Victims routinely shuttle between facilities during critical treatment windows, increasing mortality rates.

FMC Abuja pushed back, claiming they had anti-venom and provided immediate care. But even if true for that facility, the broader system failure remains: most hospitals lack essential antidotes, creating deadly treatment delays.

The Senate's directive is right. But it's reactive rather than preventive—addressing a system gap only after someone died from it. For the families who've lost relatives to treatable emergencies because hospitals weren't prepared, Tuesday's motion offers no justice. Just the bitter confirmation that their loved ones' deaths were indeed preventable.

And the fundamental question remains: if life-saving drugs must be mandated by Senate motion rather than embedded in basic health standards, what other treatment gaps exist that haven't yet produced a viral death to trigger regulation?